SCHEMBL4244668

SCHEMBL4244668

COc1cc(F)cc2c(Cl)cc(C)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.41
MAPT P10636 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDE2A O00408 4/20 0.39
PDE10A Q9Y233 4/20 0.39
SLC2A1 P11166 1/20 0.38
LMNA P02545 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
HSP90AA1 P07900 2/20 0.36
HSP90AB1 P08238 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
DHFR P00374 1/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
PDE5A O76074 1/20 0.34
PDE11A Q9HCR9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20521940 0.82 KMT2A (0.44) CRHR1MAPTL3MBTL1PDE2APDE10A
SCHEMBL7431819 0.81 MAPT (0.46) CRHR1MAPTL3MBTL1PDE10ALMNA
SCHEMBL4757968 0.81 MAPT (0.39) MAPTPDE2APDE10APDE4APDE4B
SCHEMBL9830058 0.81 NQO2 (0.46) CRHR1MAPTL3MBTL1SLC2A1LMNA
SCHEMBL17539137 0.80 MAPT (0.45) CRHR1MAPTL3MBTL1LMNAKDM4E
SCHEMBL20680299 0.77 MAPT (0.42) CRHR1MAPTL3MBTL1LMNA
SCHEMBL316994 0.75 MAPT (0.57) CRHR1MAPTL3MBTL1SLC2A1LMNA
SCHEMBL29393886 0.75 MAPT (0.57) CRHR1MAPTL3MBTL1SLC2A1LMNA
SCHEMBL18073574 0.75 PDE2A (0.38) L3MBTL1PDE2APDE10APDE4APDE4B
SCHEMBL30615135 0.75 PDE2A (0.38) L3MBTL1PDE2APDE10APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2009-01-22 US disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed
WO-2009000085-A1 QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS PAINCEPTOR PHARMA CORPORATION (CA) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023773-A1 COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS TRPV1, TRPV2, TRPA1 CRHR1 2909/4885MAPT 2142/4885L3MBTL1 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.